While TrumpRx is making headlines for lowering the prices of popular weight loss drugs, something else has also grabbed attention of many. A video from the Oval Office from the Thursday Press Conference when President Donald Trump was announcing the deal with the drugmakers, a man had collapsed. Many claimed that the person who collapsed was Gordon Findlay, who is Novo Nordisk's executive. Dr Mehmet Oz, an American present and a physician was swift to check on the man who had collapsed. Independent journalist Eric Daugherty shared the video and wrote: "A man just passed out during President Trump's Oval Office announcement. Dr Oz Sprung into action and assisted him. Pray for him."

Is The Man Gordon Findlay?

The reason why many have identified the man as Gordon Findlay because in the video, David Ricks, CEO of Eli Lily could be heard asking, "You okay? Gordon, you okay?" Upon this, the White House Press Secretary Karoline Leavitt said in the statement that "a representative with one of the companies fainted". However, no names were given.

Also Read: TrumpRx Lowered Prices Of Popular Weight Loss Drugs; What More Does Trump's New Medical Website Offer?

Novo Nordisk later clarified the claims, and in a statement to Newsweek, the company said, "Please be aware that CEO Mike Doustdar and EVP, US operations, Dave More were the only two Novo Nordisk representatives in the Oval Office."

Dr Oz had previously also helped out at the Oval office in April, when a child fainted while he was being sworn in. A woman, who many media outlets claimed, appeared to be Oz's daughter, Daphne, escorted the girl who had fainted. Later, the White House official confirmed to Fox News Digital that the girl was family member of Oz and had recovered.

What To Do When Someone Collapses?

If someone collapses in front of you, the first need is for someone to try simple CPR or cardiopulmonary resuscitation, while medical help is on its way. What must one keep in mind if someone collapses?

Check for any danger around the person, and give the shoulders of the person who collapsed a shake. Ask them if they can hear you, notes BBC.

If there is no response, tilt their head back to ensure that the airway is clear. This may be enough for the person to again start breathing.

If they are not breathing, this is when CPR becomes important.

Also Read: Delhi Sees A 60% Surge In Patients With Eye Problems Due To Worsening Air Pollution, According To Doctor

How To Do CPR The Right Way?

As per NHS, UK, there are two correct ways to practice CPR on adults:

Hands-only CPR

This is to be carry out as a chest compression

• Start with kneeling next to the person and place the heel of your hand on the breastbone at the centre of their chest. Place the palm of your other hand on top of the hand that is on their chest and interlock your fingers.
• Position yourself so your shoulders are directly above your hands.
• Using your body weight (not just your arms), press straight down by 5 to 6cm (2 to 2.5 inches) on their chest.
• Keeping your hands on their chest, release the compression and allow their chest to return to its original position.
• Repeat these compressions at a rate of 100 to 120 times a minute until an ambulance arrives or for as long as you can.

CPR with rescue breaths

• Place the heel of your hand on the center of the person's chest, then place the palm of your other hand on top and press down by 5 to 6cm (2 to 2.5 inches) at a steady rate of 100 to 120 compressions a minute.
• After every 30 chest compressions, give 2 rescue breaths.
• Tilt the person's head gently and lift the chin up with 2 fingers. Pinch the person's nose. Seal your mouth over their mouth and blow steadily and firmly into their mouth for about 1 second. Check that their chest rises. Give 2 rescue breaths.
• Continue with cycles of 30 chest compressions and 2 rescue breaths until they begin to recover or emergency help arrives.

Ozempic is about to go on sale! With TrumpRx, a website announced by the US President Donald Trump will allow Americans to buy popular weight loss drugs at a cheaper rate. The drugmakers Eli Lilly and Novo Nordisk have agreed to match prices to the lowest paid in peer nations for all their drugs in Medicaid and for the list prices when their medications first hit the market. They will be offering primary care medicines that will reach to customers directly at a discounted price.

While popular weight loss drugs could be bought from the website at as lowest as $149 per month, what else does TrumpRx offer?

In his own words, "By taking this bold step, we are ending the era of global price gouging at the expense of American families."

Not just Novo Nordisk and Eli Lilly, in fact, it was Pfizer, which is the first US pharmaceutical group that signed up to the website. The company said that it would offer discounts of up to 85%. This is for the medicines for those not using health insurance policies to pay and for those on the government's low-cost insurance programme - Medicaid.

When Will TrumpRx Be Launched?

The plan is to launch the website in early 2026 from where consumers could buy prescribed medicines directly from pharmaceutical companies without having to go through insurance. This is also to aid those under the Medicaid programme, which is a federal government programme for adults and children from lower-income backgrounds. The beneficiaries will have access to the drugs at a discounted prices, which is closer to those paid by national health services in foreign countries, known as the "most favoured nation" prices.

What Does "Most Favoured Nation" Prices Mean?

"Most Favoured Nation" or MFN prices are those that the national health services in countries including Canada, France, Germany, Italy, Japan, the United Kingdom, Switzerland and Denmark pay the US pharmaceutical companies for prescribed drugs.

Since these medicines are exported in a bulk, the prices are lowered as the purchasing power is greater to demand of the ordinary consumers. This is why pharmaceutical companies tend to sell their drugs at a lower price outside than in their own country. Earlier this year in May, Trump, thus signed an executive order that aimed at reducing prescription drug prices in the US. He stated, "The United States will no longer subsidise the health care of foreign countries.”

How Does TrumpRx Play A Role?

Apart from the lower drug prices of popular weight loss drugs, Trump, in July had sent letters to CEOs of 17 pharmaceutical companies and ordered them to reduce their prices, based on certain promises from his end, which included:

Manufacturers will be provided with an avenue to cut out middlemen and sell medicines directly to patients

Manufacturers will be supported by trade policy in raising prices internationally

Trump had also announced new 100% tariffs on imported, branded pharmaceutical products, which will allow him to deliver the second promise.

How Will TrumpRx Benefit People?

As per a 2022 study commissioned by the Office of the Assistant Secretary for Planning and Evaluation, which is published on the US government website, the standard insulin prices in the US are 10 times higher than the prices in 33 OECD countries (Organisation for Economic Cooperation and Development). Lowering of the prices of drugs domestically, and removing the middle men could bring the prices down.

The study also found that the average gross prices in US were more than 10 times the price in France, and the United Kingdom. The prices further skyrocketed by nine times in Italy, eight times the prices in Japan, seven times the prices in Germany, and more than six times in Canada.

While many people who take insulin already pay a "net price", which is lower than the standard price, however, the net price is still 2.33 times the price paid in other countries.

TrumpRx, thus, could benefit anyone who buys drugs directly from the website. This is especially for those who do not have a health insurance in the US. As per a 2024 report from the US Census Bureau, around 8%, which makes 26 million of the US population, do not have a health insurance.

Which Medicines Will Be Sold Through TrumpRx?

Apart from Eli Lilly and Novo Nordisk's popular weight loss drugs like Zepbound, Ozempic and Wegovy, Pfizer too has shared a list of primary-care medicine, not limited to the following:

• Eucrisa: topical ointment for atomic dermatitis at an 80% discount
• Xeljanz: an oral medication for types of arthritis at a 40% discount
• Zavzpret: a drug to treat migraines at a 50% discount
• Duavee: to treat menopause symptoms at around an 85% discount.
• Toviaz: a drug for overactive bladder.

TrumpRx: US President Donald Trump had announced this week that his administration plans to roll out a new website, called TrumpRx, which will allow Americans to purchase prescription medications from pharmaceutical companies at discounted rates.

In a major step to address rising drug costs, the Trump administration also unveiled agreements with Eli Lilly and Novo Nordisk to reduce prices for popular GLP-1 medications like Ozempic, Wegovy, and Zepbound. These deals, part of the TrumpRx initiative, are expected to make the drugs more affordable for Medicare, Medicaid, and direct consumers starting in 2026.

Also Read: TrumpRx Lowered Prices Of Popular Weight Loss Drugs; What More Does Trump's New Medical Website Offer?

Trump Annoucement Today: What Is TrumpRx?

TrumpRx is an online platform designed to let consumers buy prescription medicines directly from the manufacturers, bypassing insurance intermediaries. The website is scheduled to launch in early 2026. Users will be able to search for the specific drug they need and be directed to the drug’s manufacturer, according to USA Today. The platform will offer prices closer to what national health services pay in other countries, following the principle of “most favoured nation” pricing. Medicaid beneficiaries—federal insurance for low-income adults and children—will also have access to the platform.

Also Read: Trump Strikes Agreement To Cut Costs of Popular Weight Loss Drugs: All You Need to Know

TrumpRx: Will The New Website Slash Prescription Drug Prices?

The website is part of a broader effort by Trump to curb high prescription drug costs in the US. In July, he sent a letter to the CEOs of 17 pharmaceutical companies demanding lower prices.

In the letter, he outlined several key points:

• Manufacturers must provide MFN (most favoured nation) prices to all Medicaid patients.
• Companies must ensure that new drugs are not sold at lower prices in other developed nations than in the US.
• Manufacturers will have an option to sell directly to patients, cutting out middlemen, but prices cannot exceed the lowest rates in other developed countries.
• Trade policies will be leveraged to support higher international pricing, with any additional revenue abroad reinvested to reduce costs for American consumers and taxpayers.

TrumpRx: Who Will Benefit Most From This Platform?

Anyone looking to buy prescription drugs directly from manufacturers, rather than through insurance, could benefit. A 2024 US Census Bureau report noted that 8% of Americans (about 26 million people) lacked health insurance in 2023, meaning they could significantly benefit from lower prices. Medicaid may also benefit, as its deal with Pfizer offers better pricing terms. Details about how this part of the program will work are not fully clear yet. Since most Americans rely on insurance for healthcare, experts believe initial adoption of the site may be limited.

TrumpRx: Trump Announces Deal With Drugmakers to Lower Cost of Weight-Loss Drugs

On Thursday, President Trump announced deals with Novo Nordisk and Eli Lilly to cut costs for the lowest doses of their popular weight-loss drugs, lowering barriers for new patients seeking treatment. Beyond government programs, the same GLP-1 drugs will be available directly to consumers via TrumpRx.gov, launching in January 2026.

The starting doses of injectable Wegovy and Zepbound will cost $350 per month but are expected to trend down to $245 over two years. Oral versions, including Novo Nordisk’s upcoming semaglutide pill and Eli Lilly’s orforglipron, will start at $149 per month once approved.

Trumprx: President Donald Trump on Thursday unveiled agreements with Eli Lilly and Novo Nordisk aimed at cutting the prices of some of their obesity medications, including upcoming pills. The move is designed to make these expensive, blockbuster treatments more accessible to Americans.

Trump Announcement Today: GLP-1 Drugs to Become Affordable for Medicare and Medicaid Beneficiaries

The deals will reduce costs for GLP-1 drugs for Medicare and Medicaid recipients starting in 2026. The Trump administration also plans to sell the medications directly to consumers at a discount via a new website, TrumpRx.gov, launching in January. For the first time, Medicare will cover obesity treatments, which could encourage private insurers to follow suit. Certain Medicare patients will pay just $50 per month for all approved GLP-1 therapies, including those for diabetes and obesity, as per USA Today.

Trumprx: Wegovy, Zepbound, and Upcoming Pills Set for Price Cuts

Starting doses of upcoming obesity pills from Eli Lilly and Novo Nordisk, pending approval, will cost $145 per month for those using Medicare, Medicaid, or TrumpRx. Novo Nordisk’s oral version of Wegovy may enter the market by year-end, while Eli Lilly’s pill, orforglipron, could launch next year. Existing injections, such as Wegovy and Zepbound, will be available at $350 per month on TrumpRx, trending down to $245 per month over two years, as per NBC News.

Trump highlighted that these drugs have rarely been covered by Medicaid and were previously not covered by Medicare for weight loss. “They’ve often cost consumers more than $1,000 per month… That ends starting today,” he said.

Trump Announcement: Most Favoured Nation Policy Expands Access

The announcements are part of the Trump administration’s ongoing push to tie U.S. drug prices to the lowest international costs under the most favored nation policy. Trump has previously reached similar deals with Pfizer, AstraZeneca, and EMD Serono.

HHS Secretary Robert F. Kennedy Jr. said this move will have a “dramatic effect on human health,” noting that all Americans, including those not on Medicaid or Medicare, will benefit from lower GLP-1 drug prices.

Eligibility and Coverage Under Medicare

• Medicare coverage will prioritize three groups:
• Overweight patients (BMI >27) with prediabetes or cardiovascular disease.
• People with obesity (BMI >30) and uncontrolled hypertension, kidney disease, or heart failure.
• Individuals with severe obesity (BMI >35).

About 10% of Medicare beneficiaries are expected to qualify for GLP-1 therapy for obesity, cardiovascular, and metabolic benefits.

Eli Lilly and Novo Nordisk Commit To Expanded Discounts

Eli Lilly and Novo Nordisk also agreed to extend lower government pricing to all 50 Medicaid programs, provide most favored nation pricing on new medicines, and offer similar discounts on their existing drugs via TrumpRx.

Eli Lilly will additionally reduce prices on its direct-to-consumer platform, LillyDirect, where Zepbound will be available starting at $299 per month for the lowest dose. Eli Lilly’s upcoming pill will start at $149 per month.

Background on Obesity Drug Coverage

Previous efforts to cover obesity drugs under Medicare, including a proposal by former President Joe Biden, were not finalized due to costs and controversy. Health experts argue that broader access could reduce long-term expenses related to obesity-related conditions.

Semaglutide is also slated for Medicare price negotiations under the Inflation Reduction Act, while tirzepatide, the active ingredient in Zepbound, may not be part of such negotiations until the decade’s end.